- Home
- OESX vs SCLXW Comparison
OESX vs SCLXW Comparison
Compare OESX & SCLXW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OESX
- SCLXW
- Stock Information
- Founded
- OESX 1996
- SCLXW N/A
- Country
- OESX United States
- SCLXW United States
- Employees
- OESX N/A
- SCLXW 115
- Industry
- OESX Building Products
- SCLXW Biotechnology: Pharmaceutical Preparations
- Sector
- OESX Consumer Discretionary
- SCLXW Health Care
- Exchange
- OESX Nasdaq
- SCLXW Nasdaq
- Market Cap
- OESX N/A
- SCLXW N/A
- IPO Year
- OESX 2007
- SCLXW N/A
- Fundamental
- Price
- OESX $0.73
- SCLXW $0.09
- Analyst Decision
- OESX Strong Buy
- SCLXW
- Analyst Count
- OESX 1
- SCLXW 0
- Target Price
- OESX $3.00
- SCLXW N/A
- AVG Volume (30 Days)
- OESX 366.5K
- SCLXW 4.0K
- Earning Date
- OESX 06-05-2025
- SCLXW 03-07-2025
- Dividend Yield
- OESX N/A
- SCLXW N/A
- EPS Growth
- OESX N/A
- SCLXW N/A
- EPS
- OESX N/A
- SCLXW N/A
- Revenue
- OESX $85,262,000.00
- SCLXW $55,152,000.00
- Revenue This Year
- OESX N/A
- SCLXW N/A
- Revenue Next Year
- OESX $17.14
- SCLXW N/A
- P/E Ratio
- OESX N/A
- SCLXW N/A
- Revenue Growth
- OESX N/A
- SCLXW 22.02
- 52 Week Low
- OESX $0.65
- SCLXW $0.18
- 52 Week High
- OESX $1.53
- SCLXW $0.18
- Technical
- Relative Strength Index (RSI)
- OESX 48.51
- SCLXW N/A
- Support Level
- OESX $0.68
- SCLXW N/A
- Resistance Level
- OESX $0.81
- SCLXW N/A
- Average True Range (ATR)
- OESX 0.07
- SCLXW 0.00
- MACD
- OESX 0.01
- SCLXW 0.00
- Stochastic Oscillator
- OESX 49.94
- SCLXW 0.00
About SCLXW Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.